According to a recent article from Medscape, Takeda Pharmaceuticals is offering a rebate for brigatinib (Alunbrig) which is used for the treatment of non-small cell lung cancer. Non-Small Cell Lung…
Compassion [kuhm-pash-uhn] noun A feeling of deep sympathy and sorrow for another who is stricken by misfortune, accompanied by a strong desire to alleviate the suffering. Compassion Corner is a…
According to a press release from Ikena Oncology, the FDA has recently accepted an Investigational New Drug (IND) application for Ikena's investigational drug candidate, IK-930. This TEAD inhibitor is intended…
A recent article in Science Alert reports on early but positive results from a first-in-human Phase 1 clinical trial of ProTide NUC-7738. About the Drug Researchers at Oxford University partnered…
On September 30, 2021, the National Organization for Rare Disorders (NORD) hosted an educational webinar titled "Rare Cancers: Breaking Down Barriers to Diagnosis, Treatment, and Research." The webinar focused on…
A new collaboration between the University of Texas's MD Anderson Cancer Center and the Rare Cancer Research Foundation aims to solve a problem that has been a major obstacle for…
Homologous Recombination (HR) gene mutations play a role in genomic stability and plasticity, and sometimes work to repair cellular DNA damage. These mutations cause genetic information to be shared between…
A recent study conducted by researchers at the Broad Institute of MIT and Harvard University uncovered that a small group of cancer cells is responsible for recurrence. Considering that most…
According to an article published in EuroNews, the National Cancer Institute has announced that MIT researchers have developed a device that can locate cancer cells during urine tests. The device…
According to a recent article in Genetic Engineering News, findings by scientists at the University of Boston’s School of Medicine and Massachusetts General Hospital (MGH) have uncovered two plausible…
An exciting article in the Guardian published last year and a confirming article published this month state that new diagnostic technology has shown ‘impressive results’. This test can spot tumors…
Some good news was reported recently in a Biospace article. Dana-Farber Cancer Institute and Harbour BioMed have agreed to combine resources and co-develop novel biotherapies for oncology and immunological…
Liver cancer has been one of the leading causes of cancer-related deaths. A recent article in HemOnc Today reports that liver cancer is perhaps one of the most difficult cancers…
According to a story from yahoo.finance.com, the medical technology company iCAD, Inc. recently held a webinar featuring several brain tumor experts that discussed the potential of an approach called intraoperative…
Most cancers are inflamed (hot tumors) and under the right conditions can be controlled by T-cells. According to a recent article in Genetic Engineering and Biology News, there is another…
No longer the new player on the team, next-generation sequencing (NGS) is well established as having an influence in clinical care. In recent years, NGS has been responsible for many…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
According to a recent article in Fierce Biotech, most cancers progress through constant cell division. Scientists at Vanderbilt University are determined to find the reason for this mysterious cell division.…
A new study published in JAMA Oncology has found that of all patients who have had cancer spread to their bones and started treatment, 2,8% have developed osteonecrosis within their jaw, also…
There is a new collaboration in the rare cancer space which could lead to improved therapies for individuals living with these conditions. Sheperd Therapeutics and Oncoheroes Biosciences have announced that…
Genetic testing is being used more frequently to screen people for the hereditary risk of cancer, according to MedCity News. While advancements have been made and research is ongoing, there…
The first patient has been dosed in a Phase 1 clinical trial, which is exploring Curis Inc.'s CA-4948 in conjunction with ibrutinib for hematologic malignancies. Examples of hematologic malignancies include…
Zymeworks Inc. has recently began enrollment for an expansion cohort of the Phase 1 trial of ZW49. ZW49 is an antibody-drug conjugate (ADC) that targets HER2 positive cancer cells. This…
In a recent press release, biopharmaceutical company Junshi Biosciences ("Junshi") announced a burgeoning collaboration with leading biologics platform company Coherus BioSciences, Inc. ("Coherus"). The pair is working to develop and…
A recent study has found that there is an increased risk of developing recurring thrombosis for cancer patients who have a history of venous thromboembolism, or VTE. The results of…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
